Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contingent consideration valuation by Year
Contingent consideration valuation — Discount rate range maximum (%) (%)
Vertex Pharmaceuticals Contingent consideration valuation: 450.0% in FY2025, down 60.0 pts from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration valuation — Discount rate range maximum (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 450.0% | -60.0 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 510.0% | +20.0 pts | Form 10-K (filed 2025-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 490.0% | -110.0 pts | Form 10-K (filed 2024-02-15) ↗ |
| FY2022 | Dec 31, 2022 | 600.0% | +370.0 pts | Form 10-K (filed 2023-02-10) ↗ |
| FY2021 | Dec 31, 2021 | 230.0% | +40.0 pts | Form 10-K (filed 2022-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 190.0% | – | Form 10-K (filed 2021-02-11) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contingent consideration valuation (%), annual FY2020–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-disc-rate-max
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.